Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome

Abstract: The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling. A policy-relevant case study is used to show the feasibility of the method and to illustrate the type of output that is generated and how these might be used to frame research recommendations. The case study relates to the use of glycoprotein IIb/IIIa antagonists for the treatment of patients with non-ST elevation acute coronary syndrome. This is an area that recently has been appraised by the National Institute for Health and Clinical Excellence.

[1]  Ronald A. Howard,et al.  Information Value Theory , 1966, IEEE Trans. Syst. Sci. Cybern..

[2]  M. Drummond,et al.  PRIORITIZING INVESTMENTS IN HEALTH TECHNOLOGY ASSESSMENT , 2000, International Journal of Technology Assessment in Health Care.

[3]  M Johannesson,et al.  On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.

[4]  Frank A. Sloan,et al.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[5]  J Chilcott,et al.  The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors. , 2003, Health technology assessment.

[6]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[7]  K M Thompson,et al.  A dynamic programming approach to the efficient design of clinical trials. , 2001, Journal of health economics.

[8]  J Townsend,et al.  Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. , 1997, Health policy.

[9]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[10]  A. Skene,et al.  Inpatient deaths from acute myocardial infarction, 1982-92: analysis of data in the Nottingham heart attack register , 1997, BMJ.

[11]  K Claxton,et al.  An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.

[12]  Kimberly M. Thompson,et al.  The Value of Improved National Exposure Information for Perchloroethylene (Perc): A Case Study for Dry Cleaners , 1997 .

[13]  Jonathan Cave,et al.  Research Planning for Food Safety: A Value-of-Information Approach , 1991 .

[14]  Kimberly M. Thompson,et al.  A Dynamic Programming Approach to Efficient Clinical Trial Design , 2001 .

[15]  C. Pritchard,et al.  Trends in Economic Evaluation , 1998 .

[16]  Laura Ginnelly,et al.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? , 2005, International journal of cardiology.

[17]  Ron Goeree,et al.  Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[19]  M Sculpher,et al.  Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. , 2005, Health technology assessment.

[20]  Gordon B. Hazen,et al.  Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  J Hjelmgren,et al.  Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[23]  J Chilcott,et al.  The role of modelling in prioritising and planning clinical trials. , 2003, Health technology assessment.

[24]  David J Torgerson,et al.  Setting priorities for research. , 2004, Health policy.

[25]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[26]  Fumie Yokota,et al.  Value of Information Literature Analysis: A Review of Applications in Health Risk Management , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  S. Parente,et al.  Priority Setting in Medical Technology and Medical Practice Assessment , 1990, Medical care.

[29]  A. M. Skene,et al.  Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction , 1993, The Lancet.

[30]  Mark Sculpher,et al.  Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling , 2000 .

[31]  Qing Zhou,et al.  Decision Making with Uncertainty , 2005, AIAI.

[32]  Howard Raiffa,et al.  Decision analysis: introductory lectures on choices under uncertainty. 1968. , 1969, M.D.Computing.

[33]  Karl Claxton,et al.  The Value of Implementation and the Value of Information: Combined and Uneven Development , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  J. Glanville,et al.  A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. , 2002, Health technology assessment.

[35]  Milton C. Weinstein,et al.  Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .

[36]  S. Edwards,et al.  Lay public's understanding of equipoise and randomisation in randomised controlled trials. , 2005, Health technology assessment.

[37]  L. Rosenberg,et al.  Exceptional economic returns on investments in medical research , 2002, The Medical journal of Australia.

[38]  M. McDonagh,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. , 2000, Health technology assessment.

[39]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[40]  A. Hall,et al.  Rapid appraisal of clinicians' reactions to guidance from the National Institute of clinical Excellence on use of glycoprotein IIb/IIIa antagonists for acute coronary syndromes , 2002 .

[41]  M. Drummond,et al.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.

[42]  A E Ades,et al.  Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  Robert Schlaifer,et al.  Probability And Statistics For Business Decisions , 1960 .

[44]  James O. Berger.  Statistical Decision Theory , 1980 .

[45]  C. Murray,et al.  Burden of disease--implications for future research. , 2001, JAMA.